We are happy to announce that Eurobio Scientific UK will undertake a brand update to align with the evolving structure of the Eurobio Scientific Group.
This new brand embodies the collective strengths of all our affiliates, combining expertise and resources to create synergies to enhance our product offerings.
November 19, 2024 - Join us for the first seminar in our new series!
“Navigating ER+ HER2- Early Breast Cancer”
The session “What's new for high-risk early breast cancer patients” will focus on CDK4/6 inhibitors in the adjuvant setting for high-risk breast cancer patients, featuring a real-life case discussion and insights into the potential role of gene expression tests, including prospective validation data in high- risk patients (UNIRAD).